In ACS, de-escalation of DAPT reduces bleeding and does not increase ischemic events vs. other DAPT strategies

Ameenathul M. Fawzy; Professor Gregory Lip

doi:10.7326/acpj202112210-138

Related publications

Letter2020

In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplatelets

Wern Yew Ding, Mark Field, Professor Gregory Lip

Letter2012

Platelet reactivity is not associated with recurrent cardiovascular events in men with a history of myocardial infarction: a cohort study

Tobias Bonten, Jaapjan D. Snoep, Mark Roest, Frits R. Rosendaal, Johanna G. van der Bom

Journal of Thrombosis and Haemostasis

Article2020

Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events

Hideyuki Kawashima, Chao Gao, Kuniaki Takahashi, Mariusz Tomaniak, Masafumi Ono, Hironori Hara, Rutao Wang, Ply Chichareon, Harry Suryapranata, Simon Walsh, James Cotton, René Köning, Benno Rensing, Joanna J. Wykrzykowska, Robbert J. de Winter, Scot Garg, Richard Anderson, Christian W. Hamm, Philippe Gabríel Steg, Yoshinobu Onuma, Patrick W. Serruys

Thrombosis and Haemostasis

Editorial Material2023

Use of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Liver Disease

Theresa Hydes, Professor Gregory Lip, Deirdre A. Lane

Letter2020

Prevalence of Risk of Thrombosis and of Bleeding and Antithrombotic Treatment in Patients with Heart Failure

Massimo Pozzoli, José González‐Costello, Antoni Bayés‐Genís, Gianfranco Sinagra, Stefan D. Anker, Andrew J.S. Coats, María G. Crespo‐Leiro, Gerasimos Filippatos, Cécile Laroche, Aldo Maggioni, Alexandre Mebazaa, Massimo Piepoli, Luigi Tavazzi